AstraZeneca Change To Inventory vs Inventory Turnover Analysis
AZN Stock | USD 76.90 0.14 0.18% |
AstraZeneca PLC financial indicator trend analysis is way more than just evaluating AstraZeneca PLC ADR prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether AstraZeneca PLC ADR is a good investment. Please check the relationship between AstraZeneca PLC Change To Inventory and its Inventory Turnover accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
Change To Inventory vs Inventory Turnover
Change To Inventory vs Inventory Turnover Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of AstraZeneca PLC ADR Change To Inventory account and Inventory Turnover. At this time, the significance of the direction appears to have almost no relationship.
The correlation between AstraZeneca PLC's Change To Inventory and Inventory Turnover is 0.19. Overlapping area represents the amount of variation of Change To Inventory that can explain the historical movement of Inventory Turnover in the same time period over historical financial statements of AstraZeneca PLC ADR, assuming nothing else is changed. The correlation between historical values of AstraZeneca PLC's Change To Inventory and Inventory Turnover is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Change To Inventory of AstraZeneca PLC ADR are associated (or correlated) with its Inventory Turnover. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Inventory Turnover has no effect on the direction of Change To Inventory i.e., AstraZeneca PLC's Change To Inventory and Inventory Turnover go up and down completely randomly.
Correlation Coefficient | 0.19 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Change To Inventory
The increase or decrease in the amount of inventory a company has over a certain period.Inventory Turnover
A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.Most indicators from AstraZeneca PLC's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into AstraZeneca PLC ADR current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. At this time, AstraZeneca PLC's Tax Provision is very stable compared to the past year. As of the 18th of May 2024, Enterprise Value is likely to grow to about 218.7 B, while Selling General Administrative is likely to drop about 11.8 B.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 1.3B | 1.3B | 1.6B | 1.7B | Depreciation And Amortization | 6.5B | 5.6B | 4.9B | 5.2B |
AstraZeneca PLC fundamental ratios Correlations
Click cells to compare fundamentals
AstraZeneca PLC Account Relationship Matchups
High Positive Relationship
High Negative Relationship
AstraZeneca PLC fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 61.4B | 66.7B | 105.4B | 96.5B | 101.1B | 106.2B | |
Short Long Term Debt Total | 18.2B | 20.4B | 30.8B | 29.2B | 28.6B | 30.1B | |
Other Current Liab | 2.1B | 508M | 748M | 1.5B | 21.7B | 22.8B | |
Total Current Liabilities | 18.1B | 20.3B | 22.6B | 26.3B | 30.5B | 32.1B | |
Total Stockholder Equity | 13.1B | 15.6B | 39.3B | 37.0B | 39.1B | 41.1B | |
Property Plant And Equipment Net | 8.3B | 8.9B | 10.2B | 9.4B | 10.5B | 6.8B | |
Net Debt | 12.9B | 12.5B | 24.5B | 23.1B | 22.8B | 23.9B | |
Retained Earnings | 2.8B | 5.3B | 1.7B | (574M) | 1.5B | 1.4B | |
Accounts Payable | 14.0B | 15.8B | 18.9B | 19.0B | 3.3B | 3.1B | |
Cash | 5.4B | 7.8B | 6.3B | 6.2B | 5.8B | 4.7B | |
Non Current Assets Total | 45.8B | 47.2B | 79.1B | 73.9B | 76.1B | 79.9B | |
Non Currrent Assets Other | 1.5B | 1.7B | 1.1B | 1.1B | 1.1B | 1.4B | |
Cash And Short Term Investments | 6.2B | 8.0B | 6.4B | 6.4B | 5.9B | 5.8B | |
Common Stock Shares Outstanding | 2.6B | 2.6B | 2.9B | 3.1B | 3.1B | 2.9B | |
Liabilities And Stockholders Equity | 61.4B | 66.7B | 105.4B | 96.5B | 101.1B | 106.2B | |
Non Current Liabilities Total | 28.7B | 30.8B | 43.5B | 33.1B | 31.4B | 33.0B | |
Inventory | 3.2B | 4.0B | 9.0B | 4.7B | 5.4B | 5.7B | |
Total Liab | 46.8B | 51.1B | 66.1B | 59.4B | 62.0B | 65.1B | |
Total Current Assets | 15.6B | 19.5B | 26.2B | 22.6B | 25.1B | 15.3B | |
Short Term Debt | 2.0B | 2.4B | 1.9B | 5.5B | 5.4B | 5.7B | |
Other Stockholder Equity | 8.4B | 8.4B | 35.6B | 35.6B | 35.6B | 37.4B | |
Other Assets | 3.5B | 4.3B | 5.3B | 4.2B | 4.8B | 5.0B | |
Intangible Assets | 20.8B | 20.9B | 42.4B | 39.3B | 38.1B | 40.0B | |
Other Liab | 10.3B | 10.5B | 13.0B | 8.5B | 9.8B | 6.7B | |
Long Term Debt | 15.7B | 17.5B | 28.1B | 23.0B | 22.4B | 11.3B | |
Good Will | 11.7B | 11.8B | 20.0B | 19.8B | 20.0B | 21.1B | |
Other Current Assets | 971M | 1.9B | 105M | 11.5B | 116M | 110.2M | |
Property Plant Equipment | 8.3B | 8.9B | 10.2B | 9.4B | 10.9B | 7.9B | |
Current Deferred Revenue | 28M | 1.6B | 1.0B | 181M | 149M | 156.5M | |
Net Receivables | 5.2B | 5.7B | 10.8B | 9.9B | 13.6B | 14.2B | |
Property Plant And Equipment Gross | 8.3B | 8.9B | 10.2B | 9.4B | 19.1B | 20.1B | |
Accumulated Other Comprehensive Income | 1.6B | 1.6B | 1.6B | 1.6B | 1.6B | 1.7B | |
Noncontrolling Interest In Consolidated Entity | 1.6B | 1.5B | 16M | 21M | 23M | 21.9M | |
Additional Paid In Capital | 8.1B | 8.1B | 35.3B | 35.3B | 35.3B | 37.1B | |
Net Tangible Assets | (19.4B) | (17.2B) | (23.1B) | (22.1B) | (19.9B) | (20.9B) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the AstraZeneca PLC ADR information on this page should be used as a complementary analysis to other AstraZeneca PLC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Complementary Tools for AstraZeneca Stock analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |
Is AstraZeneca PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.207 | Dividend Share 2.9 | Earnings Share 2.03 | Revenue Per Share 2.5512 | Quarterly Revenue Growth 0.165 |
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.